Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 31, 2015
A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin GlargineChantal Mathieu, R Ravi Shankar, Daniel Lorber, et al.Journal of Diabetes|December 2, 2015
A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic controlRobert G Moses, Elizabeth Round, Yue Shentu, et al.BMC Endocrine Disorders|April 24, 2010
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetesDebora Williams-Herman, Samuel S Engel, Elizabeth Round, et al.Journal of Diabetes Investigation|May 17, 2016
Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitusLinong Ji, Ping Han, Xiaoyue Wang, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 29, 2013
Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trialJuan C Arjona Ferreira, Dalila Corry, Carl E Mogensen, et al.Diabetes, Obesity & Metabolism|May 17, 2018
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trialPhilip D Home, Raymond L H Lam, Wendy L Carofano, et al.Current Medical Research and Opinion|March 25, 2011
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trialNir Barzilai, Hua Guo, Erin M Mahoney, et al.Diabetes, Obesity & Metabolism|May 16, 2018
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trialPriscilla A Hollander, Wendy L Carofano, Raymond L H Lam, et al.Diabetes, Obesity & Metabolism|November 6, 2018
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I StudyRonan Roussel, Santiago Duran-García, Yilong Zhang, et al.Journal of Diabetes|June 30, 2012
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetesAdrian S Dobs, Barry J Goldstein, Pablo Aschner, et al.Pageof 3